Published in J Clin Oncol on March 01, 2002
NFKBIA deletion in glioblastomas. N Engl J Med (2010) 3.96
Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide. Clin Cancer Res (2011) 2.59
Resection and survival in glioblastoma multiforme: an RTOG recursive partitioning analysis of ALA study patients. Neuro Oncol (2008) 2.07
Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. J Neurosurg (2009) 1.91
PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors. Cancer Res (2010) 1.84
EGFRvIII and DNA double-strand break repair: a molecular mechanism for radioresistance in glioblastoma. Cancer Res (2009) 1.79
MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status. Acta Neuropathol (2012) 1.74
Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. J Clin Oncol (2008) 1.65
New (alternative) temozolomide regimens for the treatment of glioma. Neuro Oncol (2008) 1.58
Immunotherapeutic approaches for glioma. Crit Rev Immunol (2009) 1.55
A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05). J Neurooncol (2008) 1.37
Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O(6)-methylguanine methyltransferase (MGMT) promoter methylation and expression. J Clin Endocrinol Metab (2010) 1.34
Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines. Mol Cancer Ther (2009) 1.28
Oncological patterns of care and outcome for 952 patients with newly diagnosed glioblastoma in 2004. Neuro Oncol (2010) 1.25
Recent advances in blood-brain barrier disruption as a CNS delivery strategy. AAPS J (2008) 1.24
Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy. J Neurooncol (2010) 1.19
Fasting enhances the response of glioma to chemo- and radiotherapy. PLoS One (2012) 1.18
Different molecular patterns in glioblastoma multiforme subtypes upon recurrence. J Neurooncol (2009) 1.17
β1 integrin targeting potentiates antiangiogenic therapy and inhibits the growth of bevacizumab-resistant glioblastoma. Cancer Res (2013) 1.12
The Wnt inhibitory factor 1 (WIF1) is targeted in glioblastoma and has a tumor suppressing function potentially by induction of senescence. Neuro Oncol (2011) 1.10
Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant glioma. Clin Cancer Res (2008) 1.10
Discriminating survival outcomes in patients with glioblastoma using a simulation-based, patient-specific response metric. PLoS One (2013) 1.07
Multifunctional nanoparticles for brain tumor imaging and therapy. Adv Drug Deliv Rev (2013) 1.07
Cilengitide: a prototypic integrin inhibitor for the treatment of glioblastoma and other malignancies. Genes Cancer (2011) 1.06
Impact of temozolomide on immune response during malignant glioma chemotherapy. Clin Dev Immunol (2012) 1.05
Response classification based on a minimal model of glioblastoma growth is prognostic for clinical outcomes and distinguishes progression from pseudoprogression. Cancer Res (2013) 1.04
Vaccination with dendritic cells loaded with allogeneic brain tumor cells for recurrent malignant brain tumors induces a CD4(+)IL17(+) response. J Immunother Cancer (2014) 1.03
Reversing the Warburg effect as a treatment for glioblastoma. J Biol Chem (2013) 1.02
Radiotherapy and temozolomide for newly diagnosed glioblastoma and anaplastic astrocytoma: validation of Radiation Therapy Oncology Group-Recursive Partitioning Analysis in the IMRT and temozolomide era. J Neurooncol (2010) 1.02
The diagnosis and treatment of pseudoprogression, radiation necrosis and brain tumor recurrence. Int J Mol Sci (2014) 1.00
Evaluation of diffusion parameters as early biomarkers of disease progression in glioblastoma multiforme. Neuro Oncol (2010) 1.00
Toxicity after radiochemotherapy for glioblastoma using temozolomide--a retrospective evaluation. Radiat Oncol (2011) 1.00
Computerized assessment of vessel morphological changes during treatment of glioblastoma multiforme: report of a case imaged serially by MRA over four years. Neuroimage (2008) 0.99
Distress and quality of life in primary high-grade brain tumor patients. Support Care Cancer (2009) 0.99
All in the head: obstacles for immune rejection of brain tumours. Immunology (2002) 0.99
Irradiation differentially affects substratum-dependent survival, adhesion, and invasion of glioblastoma cell lines. Br J Cancer (2003) 0.98
The Relationship among Hypoxia, Proliferation, and Outcome in Patients with De Novo Glioblastoma: A Pilot Study. Transl Oncol (2010) 0.98
MerTK inhibition is a novel therapeutic approach for glioblastoma multiforme. Oncotarget (2014) 0.98
Aldehyde dehydrogenase 1A1--a new mediator of resistance to temozolomide in glioblastoma. Neuro Oncol (2012) 0.98
Secondary hematological malignancies associated with temozolomide in patients with glioma. Neuro Oncol (2013) 0.97
Intraoperative fluorescence-guided resection of high-grade malignant gliomas using 5-aminolevulinic acid-induced porphyrins: a systematic review and meta-analysis of prospective studies. PLoS One (2013) 0.97
A phase II study of O6-benzylguanine and temozolomide in pediatric patients with recurrent or progressive high-grade gliomas and brainstem gliomas: a Pediatric Brain Tumor Consortium study. J Neurooncol (2011) 0.96
The role of glioma stem cells in chemotherapy resistance and glioblastoma multiforme recurrence. Expert Rev Neurother (2015) 0.96
Migration, proliferation, and invasion of human glioma cells following treatment with simvastatin. Neurosurg Rev (2003) 0.95
Toxicity profile of temozolomide in the treatment of 300 malignant glioma patients in Korea. J Korean Med Sci (2014) 0.95
Recent progress towards development of effective systemic chemotherapy for the treatment of malignant brain tumors. J Transl Med (2009) 0.95
Management of pilocytic astrocytoma with diffuse leptomeningeal spread: two cases and review of the literature. Childs Nerv Syst (2004) 0.95
Nonsteroidal anti-inflammatory drug-activated gene (NAG-1/GDF15) expression is increased by the histone deacetylase inhibitor trichostatin A. J Biol Chem (2008) 0.94
Temozolomide: The evidence for its therapeutic efficacy in malignant astrocytomas. Core Evid (2010) 0.94
Reduction of MLH1 and PMS2 confers temozolomide resistance and is associated with recurrence of glioblastoma. Oncotarget (2013) 0.94
Medical management of brain tumors and the sequelae of treatment. Neuro Oncol (2014) 0.94
A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma. Neuro Oncol (2010) 0.93
Chromosome 7 gain and DNA hypermethylation at the HOXA10 locus are associated with expression of a stem cell related HOX-signature in glioblastoma. Genome Biol (2015) 0.92
Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma. Neuro Oncol (2004) 0.91
An interleukin 13 receptor α 2-specific peptide homes to human Glioblastoma multiforme xenografts. Neuro Oncol (2011) 0.91
The future of glioblastoma therapy: synergism of standard of care and immunotherapy. Cancers (Basel) (2014) 0.91
Temozolomide chemotherapy in patients with recurrent malignant gliomas. J Korean Med Sci (2006) 0.91
Effect of imaging and catheter characteristics on clinical outcome for patients in the PRECISE study. J Neurooncol (2010) 0.89
Treatment of primary glioblastoma multiforme with cetuximab, radiotherapy and temozolomide (GERT)--phase I/II trial: study protocol. BMC Cancer (2006) 0.89
Cost of temozolomide therapy and global care for recurrent malignant gliomas followed until death. Neuro Oncol (2005) 0.89
Enhancement of radiosensitivity in human glioblastoma cells by the DNA N-mustard alkylating agent BO-1051 through augmented and sustained DNA damage response. Radiat Oncol (2011) 0.88
Computational modeling of tumor response to vascular-targeting therapies--part I: validation. Comput Math Methods Med (2011) 0.88
Neuronatin in a subset of glioblastoma multiforme tumor progenitor cells is associated with increased cell proliferation and shorter patient survival. PLoS One (2012) 0.88
Advances in the management of glioblastoma: the role of temozolomide and MGMT testing. Clin Pharmacol (2012) 0.88
A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients With Glioblastoma. Int J Radiat Oncol Biol Phys (2015) 0.87
Concurrent radiotherapy with temozolomide followed by adjuvant temozolomide and cis-retinoic acid in children with diffuse intrinsic pontine glioma. Neuro Oncol (2008) 0.86
Potential application of temozolomide in mesenchymal stem cell-based TRAIL gene therapy against malignant glioma. Stem Cells Transl Med (2014) 0.86
Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy. J Neurooncol (2009) 0.86
Temozolomide and radiotherapy versus radiotherapy alone in high grade gliomas: a very long term comparative study and literature review. Biomed Res Int (2015) 0.86
Molecular profiling of childhood cancer: Biomarkers and novel therapies. BBA Clin (2014) 0.86
Extended adjuvant temozolomide with cis-retinoic acid for adult glioblastoma. Curr Oncol (2012) 0.85
Lonafarnib (SCH66336) improves the activity of temozolomide and radiation for orthotopic malignant gliomas. J Neurooncol (2011) 0.85
Oxidative cytotoxic agent withaferin A resensitizes temozolomide-resistant glioblastomas via MGMT depletion and induces apoptosis through Akt/mTOR pathway inhibitory modulation. Invest New Drugs (2014) 0.85
Cytomegalovirus associated colonic pseudotumor: a consequence of iatrogenic immunosuppression in a patient with primary brain tumor receiving radiation and temozolomide. J Neurooncol (2009) 0.85
Clinical significance and novel mechanism of action of kallikrein 6 in glioblastoma. Neuro Oncol (2013) 0.84
CRAdRGDflt-IL24 virotherapy in combination with chemotherapy of experimental glioma. Cancer Gene Ther (2009) 0.84
Molecular targeting of intracellular compartments specifically in cancer cells. Genes Cancer (2010) 0.83
Applications of emerging molecular technologies in glioblastoma multiforme. Expert Rev Neurother (2008) 0.83
Towards personalized therapy for patients with glioblastoma. Expert Rev Anticancer Ther (2011) 0.83
Comparison of the clinical efficacy of temozolomide (TMZ) versus nimustine (ACNU)-based chemotherapy in newly diagnosed glioblastoma. Neurosurg Rev (2013) 0.82
Cord blood stem cells inhibit epidermal growth factor receptor translocation to mitochondria in glioblastoma. PLoS One (2012) 0.82
The outcomes of concomitant chemoradiotherapy followed by adjuvant chemotherapy with temozolomide for newly diagnosed high grade gliomas : the preliminary results of single center prospective study. J Korean Neurosurg Soc (2008) 0.82
Attenuated AMPA receptor expression allows glioblastoma cell survival in glutamate-rich environment. PLoS One (2009) 0.82
Are we done with dose-intense temozolomide in recurrent glioblastoma? Neuro Oncol (2014) 0.82
Inhibition of Fatty Acid Synthase Decreases Expression of Stemness Markers in Glioma Stem Cells. PLoS One (2016) 0.82
Microvesicles as a Biomarker for Tumor Progression versus Treatment Effect in Radiation/Temozolomide-Treated Glioblastoma Patients. Transl Oncol (2014) 0.82
T cells enhance stem-like properties and conditional malignancy in gliomas. PLoS One (2010) 0.81
Molecularly targeted therapies for recurrent glioblastoma: current and future targets. Neurosurg Focus (2014) 0.81
Contemporary murine models in preclinical astrocytoma drug development. Neuro Oncol (2014) 0.81
Recent advances in combined modality therapy. Oncologist (2010) 0.81
Immunotherapy for malignant glioma. Surg Neurol Int (2015) 0.81
Protein Phosphatase 2A Inhibition with LB100 Enhances Radiation-Induced Mitotic Catastrophe and Tumor Growth Delay in Glioblastoma. Mol Cancer Ther (2015) 0.80
Concurrent therapy to enhance radiotherapeutic outcomes in glioblastoma. Ann Transl Med (2016) 0.80
Temozolomide during and after Radiotherapy for Newly Diagnosed Glioblastomas : A Prospective Multicenter Study of Korean Patients. J Korean Neurosurg Soc (2012) 0.80
Standard of care and future pharmacological treatment options for malignant glioma: an urgent need for screening and identification of novel tumor-specific antigens. Expert Opin Pharmacother (2014) 0.79
Recurrent brain tumour: the impact of illness on patient's life. Support Care Cancer (2011) 0.79
In vitro effects of Cyberknife-driven intermittent irradiation on glioblastoma cell lines. Neurol Sci (2011) 0.79
Antitumor activity of a polypyridyl chelating ligand: in vitro and in vivo inhibition of glioma. ASN Neuro (2015) 0.79
Treatment of newly diagnosed glioblastoma multiforme. J Clin Oncol (2002) 0.79
The role of radiotherapy and chemotherapy in the treatment of primary adult high grade gliomas: assessment of patients for these treatment approaches and the common immediate side effects. ISRN Oncol (2012) 0.78
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med (2005) 74.55
MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med (2005) 29.65
Mapping the structural core of human cerebral cortex. PLoS Biol (2008) 16.38
Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol (2008) 6.41
Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med (2012) 5.80
Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. Blood (2007) 5.55
Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med (2012) 5.44
HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity. Curr Biol (2006) 5.17
KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer (2006) 4.92
Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood (2006) 4.61
Mapping human whole-brain structural networks with diffusion MRI. PLoS One (2007) 4.54
Neurosurgery and shaving: what's the evidence? J Neurosurg (2011) 3.73
Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol (2007) 3.53
Perfusion-CT assessment of infarct core and penumbra: receiver operating characteristic curve analysis in 130 patients suspected of acute hemispheric stroke. Stroke (2006) 3.49
Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res (2004) 3.47
Understanding diffusion MR imaging techniques: from scalar diffusion-weighted imaging to diffusion tensor imaging and beyond. Radiographics (2006) 3.37
Notch signaling controls the generation and differentiation of early T lineage progenitors. Nat Immunol (2005) 3.26
Short- and long-term mortality with localized prostate cancer. Arch Intern Med (2007) 3.23
Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol (2010) 3.05
Notch signaling is an important regulator of type 2 immunity. J Exp Med (2005) 2.87
Complete remission with tyrosine kinase inhibitors in renal cell carcinoma. J Clin Oncol (2012) 2.56
Prognostic accuracy of cerebral blood flow measurement by perfusion computed tomography, at the time of emergency room admission, in acute stroke patients. Ann Neurol (2002) 2.52
Notch signaling modulates proliferation and differentiation of intestinal crypt base columnar stem cells. Development (2011) 2.45
Automatic quality assessment in structural brain magnetic resonance imaging. Magn Reson Med (2009) 2.43
Changing paradigms--an update on the multidisciplinary management of malignant glioma. Oncologist (2006) 2.42
Postcarotid endarterectomy hyperperfusion or reperfusion syndrome. Stroke (2004) 2.36
Health-related quality of life in patients with glioblastoma: a randomised controlled trial. Lancet Oncol (2005) 2.26
Notch signaling in cancer. Cancer Biol Ther (2002) 2.20
Classification of human astrocytic gliomas on the basis of gene expression: a correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes. Cancer Res (2003) 2.15
Dorsal fractures of the triquetrum: MRI findings with an emphasis on dorsal carpal ligament injuries. AJR Am J Roentgenol (2013) 2.12
3-T direct MR arthrography of the wrist: value of finger trap distraction to assess intrinsic ligament and triangular fibrocartilage complex tears. Eur J Radiol (2013) 2.09
Aquaporins in brain: distribution, physiology, and pathophysiology. J Cereb Blood Flow Metab (2002) 2.08
MR connectomics: Principles and challenges. J Neurosci Methods (2010) 2.02
CBX8, a polycomb group protein, is essential for MLL-AF9-induced leukemogenesis. Cancer Cell (2011) 2.01
Requirement for Dot1l in murine postnatal hematopoiesis and leukemogenesis by MLL translocation. Blood (2011) 1.99
Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Clin Cancer Res (2004) 1.95
Selective thymus settling regulated by cytokine and chemokine receptors. J Immunol (2007) 1.92
Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy. Brain (2012) 1.92
Retracted Marker-independent identification of glioma-initiating cells. Nat Methods (2010) 1.84
An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patients. Eur J Cancer (2010) 1.84
Spot-scanning proton radiation therapy for recurrent, residual or untreated intracranial meningiomas. Radiother Oncol (2004) 1.81
(11)C-acetate PET in the early evaluation of prostate cancer recurrence. Eur J Nucl Med Mol Imaging (2006) 1.79
Evaluation of [(18)F]-choline PET/CT for staging and restaging of prostate cancer. Eur J Nucl Med Mol Imaging (2007) 1.79
Ex vivo characterization of human CD8+ T subsets with distinct replicative history and partial effector functions. Blood (2003) 1.78
Tribbles homolog 2 inactivates C/EBPalpha and causes acute myelogenous leukemia. Cancer Cell (2006) 1.76
Assessment of various strategies for 18F-FET PET-guided delineation of target volumes in high-grade glioma patients. Eur J Nucl Med Mol Imaging (2008) 1.76
MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status. Acta Neuropathol (2012) 1.74
New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site. J Immunol (2006) 1.74
Homing phenotypes of tumor-specific CD8 T cells are predetermined at the tumor site by crosspresenting APCs. Immunity (2005) 1.74
Potential role of intensity-modulated photons and protons in the treatment of the breast and regional nodes. Int J Radiat Oncol Biol Phys (2003) 1.71
Core binding factors are necessary for natural killer cell development and cooperate with Notch signaling during T-cell specification. Blood (2008) 1.67
T-ing up inflammation in fat. Nat Med (2009) 1.66
Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis. Int J Cancer (2006) 1.65
Cerebral metabolic effects of exogenous lactate supplementation on the injured human brain. Intensive Care Med (2014) 1.64
Cervical sympathetic block to reverse delayed ischemic neurological deficits after aneurysmal subarachnoid hemorrhage. Stroke (2003) 1.61
Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients. Neuropsychopharmacology (2007) 1.61
The connectome viewer toolkit: an open source framework to manage, analyze, and visualize connectomes. Front Neuroinform (2011) 1.60
From the cradle to the grave: activities of GATA-3 throughout T-cell development and differentiation. Immunol Rev (2010) 1.60
Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma. Immunol Rev (2002) 1.58
Notch signaling specifies megakaryocyte development from hematopoietic stem cells. Cell Stem Cell (2008) 1.58
Mapping the human connectome at multiple scales with diffusion spectrum MRI. J Neurosci Methods (2011) 1.56
Time course of aquaporin expression after transient focal cerebral ischemia in mice. J Neurosci Res (2006) 1.56
GATA-3 is required for early T lineage progenitor development. J Exp Med (2009) 1.56
Relationship between brain perfusion computed tomography variables and cerebral perfusion pressure in severe head trauma patients. Crit Care Med (2004) 1.55
Accuracy of brain multimodal monitoring to detect cerebral hypoperfusion after traumatic brain injury*. Crit Care Med (2015) 1.55
Anoxia induces macrophage inhibitory cytokine-1 (MIC-1) in glioblastoma cells independently of p53 and HIF-1. Oncogene (2002) 1.52
Multi-phase post-mortem CT angiography: development of a standardized protocol. Int J Legal Med (2010) 1.51
Unusual locations of hemangioblastomas. Case illustration. J Neurosurg (2002) 1.51
Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor. J Clin Oncol (2008) 1.50
Selective-targeted extra-intracranial bypass surgery in complex middle cerebral artery aneurysms: correctly identifying the recipient artery using indocyanine green videoangiography. Neurosurgery (2012) 1.49
Overview of disc arthroplasty-past, present and future. Acta Neurochir (Wien) (2009) 1.49
Great expectations: really the novel predictor of outcome after spinal surgery? Spine (Phila Pa 1976) (2009) 1.47
The connectome mapper: an open-source processing pipeline to map connectomes with MRI. PLoS One (2012) 1.45
Guidelines for target volume definition in post-operative radiotherapy for prostate cancer, on behalf of the EORTC Radiation Oncology Group. Radiother Oncol (2007) 1.44
Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. J Clin Oncol (2010) 1.44
Notch pathway activity identifies cells with cancer stem cell-like properties and correlates with worse survival in lung adenocarcinoma. Clin Cancer Res (2013) 1.43
Frontobasal interhemispheric trans-lamina terminalis approach for suprasellar lesions. Neurosurgery (2005) 1.43
Feasibility and efficacy of subcutaneous amifostine therapy in patients with head and neck cancer treated with curative accelerated concomitant-boost radiation therapy. Arch Otolaryngol Head Neck Surg (2006) 1.42
The assessment of complications after spine surgery: time for a paradigm shift? Spine J (2013) 1.42
Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood (2003) 1.40
Call for uniform neuropsychological assessment after aneurysmal subarachnoid hemorrhage: Swiss recommendations. Acta Neurochir (Wien) (2015) 1.40
Appropriateness criteria for surgery improve clinical outcomes in patients with low back pain and/or sciatica. Spine (Phila Pa 1976) (2010) 1.39
Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. J Clin Invest (2014) 1.38
Small cell lung cancer: state of the art and future perspectives. Lung Cancer (2004) 1.37
The diagnostic value of multimodal intraoperative monitoring (MIOM) during spine surgery: a prospective study of 1,017 patients. Eur Spine J (2007) 1.36
Immuno-monitoring of CD8+ T cells in whole blood versus PBMC samples. J Immunol Methods (2005) 1.33
Recurrent bacteremia with Helicobacter cinaedi: case report and review of the literature. BMC Infect Dis (2006) 1.33